Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | CHAT | P28329 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769401 | 1.00 | NFE2L2 (0.44) | NFE2L2RELACYP1A2CYP2C9HPGD | |
| SCHEMBL3771665 | 0.84 | CCNB2 (0.45) | FBP1MAOBNR1I2 | |
| SCHEMBL3764328 | 0.84 | RELA (0.42) | RELAFBP1MAPTMAOBNR1I2 | |
| SCHEMBL3771661 | 0.84 | CCNB2 (0.45) | FBP1MAOBNR1I2 | |
| SCHEMBL3764325 | 0.84 | RELA (0.42) | RELAFBP1MAPTMAOBNR1I2 | |
| SCHEMBL3776956 | 0.83 | NFE2L2 (0.47) | NFE2L2RELACYP1A2FBP1CHRM5 | |
| SCHEMBL3776959 | 0.83 | NFE2L2 (0.47) | NFE2L2RELACYP1A2FBP1CHRM5 | |
| SCHEMBL3781097 | 0.82 | MAOB (0.40) | NFE2L2CYP1A2FBP1GRIK1GRIK2 | |
| SCHEMBL3781100 | 0.82 | MAOB (0.40) | NFE2L2CYP1A2FBP1GRIK1GRIK2 | |
| SCHEMBL3291424 | 0.82 | NR1I2 (0.50) | RELACYP1A2CYP2C9HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393780-A1 | HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2011-12-14 | — | — | EP | disclosed |
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-12-16 | — | — | US | disclosed |
| WO-2010089119-A1 | HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GRIK5, HRH2 | NFE2L2 4506/4885RELA 4648/4885CYP1A2 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.